References
- 1. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000; 105:14-20.10.1542/peds.105.1.14
- 2. Nakwan N, Nakwan N, Wannaro J. Predicting mortality outcome in infants with persistent pulmonary hypertension of the newborn with the Score for Neonatal Acute Physiology-Version II (SNAP-II) in Thai neonates. J Perinat Med. 2011; 39:311-5.
- 3. Vargas-Origel A, Gomez-Rodríguez G, Aldana- Valenzuela C, Vela-Huerta MM, Alarcon-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol. 2010; 27:225-30.10.1055/s-0029-1239496
- 4. Nakwan N, Nakwan N, Choksuchat D, Saksawad R, Thammachote P. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr. 2009; 98:1683-5.10.1111/j.1651-2227.2009.01386.x
- 5. Nakwan N, Nakwan N, Wanaro J. Persistent pulmonary hypertension of the newborn successfully treated with beraprost sodium: a retrospective chart review. Neonatology. 2011; 99:33-7.
- 6. Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol. 2012; 32:608-13.10.1038/jp.2011.157
- 7. Ewert R, Opitz CF, Wensel R, Winkler J, Halank M, Felix SB. Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol. 2007; 96:211-7.10.1007/s00392-007-0490-3
- 8. Hoeper MM, Schwarze M, Ehlerding S, Adler- Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000; 342:1866-70.
- 9. Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv. 2009; 73:98-104.
- 10. Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J Med Assoc Thai. 2007; 90:167-70.
- 11. De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as ‘rescue’ therapy for pulmonary hypertension of the neonate. Paediatr Anaesth. 2007; 17:394-5.10.1111/j.1460-9592.2006.02104.x
- 12. Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. Cardiol Young. 2003; 13:361-3 .10.1017/S1047951103000726
- 13. Greenough A, Khetriwal B. Pulmonary hypertension in the newborn: Paediatr Respir Rev. 2005; 6:111-6.10.1016/j.prrv.2005.03.005
- 14. Schror K, Darius H, Matzky R, Ohlendorf R. The anti-platelet and cardiovascular actions of a new carbacyclin derivative (ZK36374) - equipotent to PGI2 in vitro. Arch Pharmacol. 1981; 316:252-5.
- 15. Bugiardini R, Galvani M, Ferrini D, Gridelli C, Mari L, Puddu P, et al. Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris. Am J Cardiol. 1986; 58:453-9.10.1016/0002-9149(86)90014-7
- 16. Kaukinen S, Ylitalo P, Pessi T, Vapaatalo H. Hemodynamic effects of iloprost, a prostacyclin analog. Clin Pharmacol Ther. 1984; 36:464-9.10.1038/clpt.1984.205
- 17. Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J. 2002; 20:339-43.10.1183/09031936.02.02462001
- 18. Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 1998: 79;175-9.10.1136/hrt.79.2.175